Facebook Instagram Linkedin Youtube
Home Search

ultimovacs - search results

If you're not happy with the results, please do another search
Ultimovacs receives Orphan Drug Designation from EMA

Ultimovacs receives Orphan Drug Designation from EMA

Carlos de Sousa, CEO Ultimovacs

Ultimovacs CEO: “Data could put us at the forefront of cancer...

Adjutec is getting closer to phase I

Adjutec CEO on preparing for phase I

All sessions from BioStock Life Science Fall Summit 2023

Video from day 1 of BioStock Life Science Fall Summit 2023

Ultimovacs_NIPU_survival

Ultimovacs reaches proof of concept with UV1 cancer vaccine

Jens Bjørheim, CMO Ultimovacs

Ultimovacs CMO explains phase II mesothelioma data

Ultimovacs i kampen mot mesoteliom

Ultimovacs in the fight against mesothelioma

Ultimovacs INITIUM study timeline

Ultimovacs updates INITIUM study timeline

Ultimovacs on track for phase II

Ultimovacs on track to phase II readout

BioStock Life Science Fall Summit Mingle interviews

Watch interviews from BioStock Life Science Fall Summit

The innovative force behind Ultimovacs’ cancer vaccine

Watch the BioStock Life Science Fall Summit!

Uppsala's life science sector continues to grow

Uppsala’s life science sector continues to grow

History behind Keytruda

Can Nordic companies extend the life of Keytruda?

Ultimovacs clinical transition

Ultimovacs poised for major clinical transition

Ultimovacs positive data

Ultimovacs shows positive three-year data in skin cancer

Summit watch all presentations and interviews

BioStock Life Science Fall Summit 2022

Ultimovacs studie fullrekryterad

Ultimovacs’ malignant melanoma study fully recruited

Sara Mangsbo Ultimovacs

An in-depth look at Ultimovacs’ cancer vaccine

Ultimovacs Q1

Ultimovacs keeps delivering in Q1

Ultimovacs Patent Protection

Ultimovacs protects cancer vaccine technology until 2037

cancer vaccines

Cancer vaccines – a new frontier in immuno-oncology

Ultimovacs wave of positive momentum

Ultimovacs to ride wave of positive momentum in 2022

Ultimovacs progresses to last cohort in TENDU study

Ultimovacs progresses to last cohort in TENDU study

Ultimovacs sees first patient enrolled in DOVACC trial

Ultimovacs sees first patient enrolled in DOVACC trial

Ultimovacs’ UV1 granted orphan drug designation

Ultimovacs’ UV1 granted orphan drug designation

Ultimovacs progresses on several fronts

Ultimovacs progresses on several fronts

BioStock Studio: Ultimovacs reaches key milestones with UV1

BioStock Studio: Ultimovacs reaches key milestones with UV1

Ultimovacs launches fifth phase II trial with UV1

Ultimovacs launches fifth phase II trial with UV1

Ultimovacs Fast Track

Ultimovacs receives dual FDA Fast Track for UV1

BioStock Life Science Summit 20 – 21 Oktober 2021

Join us for the BioStock Life Science Summit on October 20...

positive data

Positive phase I data for Ultimovacs

Ultimovacs enters next step in new vaccine platform development

Ultimovacs strengthens clinical validation of UV1 in Q2

Q3 report indicates advancements for Ultimovacs

Ultimovacs initiates fourth phase II trial with UV1

Ultimovacs announces collaboration with AstraZeneca

Ultimovacs presents INITIUM study design at AACR

Ultimovacs’ clinical data presented at ASCO

Innovation in focus at BioStock Life Science Spring Summit 2021

New data gives weight to Ultimovacs’s cancer vaccine

Ultimovacs Begins Clinical Evaluation of Novel TET-Platform

Ultimovacs can look back on strong 2020

Watch company presentations & panels from the BioStock Life Science Summit...

Strong line-up at the BioStock Life Science Summit 2020

Ultimovacs in the fight against Melanoma

Ultimovacs Cancer Vaccine

Ultimovacs on track to develop universal cancer vaccine

© BioStock 2024